Liquidseq Actionable Gene Panel [23] Test
About Liquidseq Actionable Gene Panel [23] Test
| Field | Value |
|---|---|
| Also Known As | Liquid Biopsy Actionable Gene Panel, ctDNA 23-Gene Panel, Circulating Tumour DNA NGS Panel, Blood-Based Genomic Profiling Test |
| Sample Type | Peripheral blood (plasma) collected in specialised cell-free DNA stabilisation tubes |
| Fasting Required | No fasting required |
| Report Time | 30 days |
| Recommended For | Adults with solid tumours (any gender), particularly patients with advanced or metastatic cancer |
| Price | Starting at ₹30,000 |
What Is a Liquidseq Actionable Gene Panel [23]?
The LiquidSeq actionable gene panel [23] test is a blood-based genomic profiling test that analyses circulating tumour DNA (ctDNA) shed by cancer cells into the bloodstream. It uses next-generation sequencing (NGS) to examine 23 clinically relevant genes linked to targeted cancer therapies. Also known as a liquid biopsy, this test provides genetic information about a tumour without the need for a surgical tissue sample. A venous blood sample collected in a specialised tube is used for analysis.
What Does a Liquidseq Actionable Gene Panel [23] Test Measure?
The LiquidSeq actionable gene panel [23] test analyses ctDNA fragments in the blood for mutations across 23 cancer-associated genes. Each gene is associated with specific cancers and treatment options.
The 23 genes included in this panel are listed below.
| Gene | Relevance |
|---|---|
| EGFR | Guides targeted therapy in lung cancer |
| KRAS | Affects treatment response in colorectal and lung cancers |
| ALK | Rearrangements indicate eligibility for ALK inhibitor therapy |
| BRAF | V600E mutation guides melanoma and colorectal cancer treatment |
| PIK3CA | Relevant in breast cancer targeted therapy |
| ERBB2 (HER2) | Amplifications guide therapy selection |
| ERBB3 | Associated with resistance to HER2-targeted treatments |
| ROS1 | Fusions indicate targeted therapy options in lung cancer |
| MET | Amplifications and exon 14 mutations are actionable |
| RET | Fusions guide therapy in thyroid and lung cancers |
| NRAS | Relevant in melanoma and colorectal cancer |
| IDH1 | Mutations guide therapy in glioma and cholangiocarcinoma |
| IDH2 | Associated with blood cancers and solid tumours |
| KIT | Mutations relevant in gastrointestinal stromal tumours |
| PDGFRA | Associated with specific gastrointestinal and other cancers |
| RAF1 | Involved in cell signalling pathways in multiple cancers |
| AKT1 | Associated with cell growth and cancer progression |
| CTNNB1 | Mutations relevant in colorectal and liver cancers |
| ESR1 | Guides hormone therapy in breast cancer |
| FOXL2 | Associated with granulosa cell tumours |
| GNA11 | Relevant in uveal melanoma |
| GNAQ | Relevant in uveal melanoma |
| TP53 | Tumour suppressor gene providing prognostic information |
Why Is a Liquidseq Actionable Gene Panel [23] Done?
A doctor may recommend this test for several clinical reasons, including guiding treatment decisions and monitoring disease progression. The sections below cover the most common situations where this panel is used.
Common Symptoms That May Require This Test
The following clinical situations or symptoms may lead a doctor to recommend this test.
- Unexplained or persistent weight loss in a patient with known or suspected cancer
- Persistent fatigue not explained by other causes
- Suspected spread of cancer to other organs (metastatic disease)
- Disease progression while on an existing cancer treatment
- Insufficient tumour tissue available from a previous biopsy for molecular testing
- Need for treatment selection guidance based on the tumour's genetic profile
- Monitoring of therapy response over time
Conditions This Test Can Help Detect
This panel can identify actionable mutations across a range of solid tumour types. The conditions it can help assess include the following.
- Non-small cell lung cancer (NSCLC) driver mutations
- Breast cancer targetable alterations, including HER2 and ESR1 mutations
- Colorectal cancer treatment resistance markers
- Melanoma BRAF mutations
- Cholangiocarcinoma (bile duct cancer) with IDH1 mutations or FGFR fusions
- Gastric and gastrointestinal cancers with actionable alterations
- Treatment resistance mutations, such as EGFR T790M in lung cancer
Liquidseq Actionable Gene Panel [23] for Chronic Disease Monitoring
Repeated liquid biopsy testing allows oncologists to track how a tumour is changing over time without repeated surgical procedures. Through analysis of ctDNA levels across multiple time points, the test can indicate whether a treatment is working, whether resistance is emerging, or whether residual disease remains after curative treatment. This makes it a useful tool for long-term cancer management and treatment adjustment.
How to Prepare and What to Expect
No complex preparation is needed for this test. The steps below explain what to do before and during your appointment.
Do You Need to Fast?
No fasting is required for this test. You may eat and drink normally before your blood draw.
Practical Tips Before Your Test
The following steps will help ensure a smooth experience and accurate results.
- Bring a detailed clinical history, including your symptoms, previous test results, and treatment records, as this is required for the test
- Inform the phlebotomist and your doctor about all current medications, including chemotherapy or targeted therapy agents
- Bring any previous tumour biopsy reports or imaging results to your appointment
- Drink adequate water before your appointment to make the blood draw easier
- Discuss any recent cancer treatments with your doctor, as these may temporarily affect ctDNA levels
Step-by-Step Procedure
The LiquidSeq actionable gene panel [23] test involves the following steps:
- A trained phlebotomist will clean the venepuncture site, usually on your inner arm, with an antiseptic wipe.
- A needle is gently inserted into a vein to collect 10 ml of blood into a specialised Streck tube designed to stabilise cell-free DNA.
- After collection, the tubes are inverted gently several times to mix the contents with the stabilising agent.
- The sample is stored at 2 to 8 degrees Celsius and sent to the laboratory according to the required cold chain conditions.
- In the laboratory, plasma is separated from the blood and processed for ctDNA extraction.
- NGS analysis is performed on the extracted cell-free DNA, and results are prepared and reported within the turnaround period.
Factors That Can Affect Accuracy
Several factors may influence the reliability of results. These include the following.
- Low tumour burden, particularly in early-stage cancers, where ctDNA levels may be below the detection limit
- Recent chemotherapy or radiotherapy, which can transiently alter ctDNA levels in the blood
- Improper sample handling or delays in processing, which can degrade cell-free DNA
- Genetic differences within a tumour (tumour heterogeneity) that may not be fully captured in a blood sample
- Non-malignant conditions that may occasionally produce DNA fragments resembling tumour-derived mutations
Understanding Your Liquidseq Actionable Gene Panel [23] Test Results
Results from this panel require expert interpretation by an oncologist familiar with genomic medicine. The table below outlines what the key findings generally indicate.
| Finding | What It May Mean |
|---|---|
| No mutations detected (negative) | No pathogenic variants identified in the 23 genes; ctDNA below detection threshold |
| Mutation detected (positive) | Presence of a pathogenic or likely pathogenic variant in one or more genes |
| Low mutant allele frequency | Low proportion of tumour DNA in the sample; may reflect early-stage disease or good treatment response |
| High mutant allele frequency | Higher proportion of tumour DNA; may indicate greater tumour burden |
Disclaimer: These ranges are general guidelines. Your doctor will interpret your results based on your age, health history, and other factors. Always consult a qualified healthcare professional for personalised medical advice.
Results During Special Conditions
Certain conditions may affect how results should be read.
High ctDNA levels are generally associated with a greater tumour burden and may carry a less favourable prognosis, whereas a decline in ctDNA levels during treatment often suggests a positive response.
Conversely, very low or undetectable ctDNA does not rule out cancer; tissue biopsy may still be needed if clinical suspicion is high. Recent radiotherapy or chemotherapy may also temporarily alter ctDNA levels, which should be factored into the interpretation of results.
How to Maintain Healthy Levels
While this test measures cancer-related gene mutations rather than lifestyle parameters, the following steps support your overall cancer care.
- Attend all scheduled follow-up appointments with your oncologist to track disease status over time
- Keep all genomic test reports and medical records organised and readily available for your healthcare team
- Report any new or worsening symptoms to your doctor promptly, rather than waiting for the next scheduled visit
Lupin Diagnostics Liquidseq Actionable Gene Panel [23] Test Price
The Liquidseq Actionable Gene Panel [23] test cost at Lupin Diagnostics starts at ₹30,000. This test requires a visit to a Lupin Diagnostics centre; home collection is not available for this test due to the specialised sample handling requirements.
| City | Approximate Price (₹) |
|---|---|
| Mumbai | 30000 |
| Pune | 30000 |
| Bangalore | 30000 |
| Chennai | 30000 |
Disclaimer: Prices are indicative and may vary by location. Please confirm the current price at the time of booking.
How to Book
Follow these steps to schedule your Liquidseq Actionable Gene Panel [23] test online booking or in-person appointment.
- Select the test on the Lupin Diagnostics website.
- Choose your city and preferred centre location.
- Visit the centre at your scheduled time for sample collection.
- Receive your report via email or WhatsApp within the stipulated turnaround time.
Frequently Asked Questions
A liquid biopsy analyses fragments of tumour DNA that circulate in the blood, whereas a tissue biopsy requires surgical removal of a sample from the tumour site. The LiquidSeq actionable gene panel [23] test offers a less invasive alternative, allows repeated sampling over time, and can capture genetic information from multiple tumour sites simultaneously.
This test is recommended for adults with advanced or metastatic solid tumours who need treatment guidance. It is particularly useful when tumour tissue is unavailable, insufficient, or difficult to obtain safely. Patients whose cancer has progressed on existing treatment may also benefit from this panel to identify new actionable targets.
The report for the LiquidSeq actionable gene panel [23] test is delivered within 30 days from the date of sample receipt at the laboratory. Please factor this into your treatment planning timeline and discuss any urgency with your oncologist.
No. A negative result means no mutations were detected in the 23 genes analysed; it does not rule out cancer. ctDNA levels may be too low to detect in early-stage disease or when tumour burden is minimal. Your doctor may recommend a tissue biopsy if clinical suspicion remains high despite a negative liquid biopsy result.
Yes. Repeated testing over the course of treatment allows your oncologist to track changes in ctDNA levels. A decline in detectable mutations often suggests a positive treatment response, while rising levels or new mutations may indicate emerging resistance, prompting a review of your treatment plan.
The procedure involves a straightforward blood draw, similar to a routine blood test. A phlebotomist collects 10 ml of blood into a specialised stabilisation tube. The process takes only a few minutes and does not require any sedation or hospital admission.
No fasting or special preparation is needed. You should bring your clinical history, previous biopsy reports, and a list of current medications to your appointment. Staying well hydrated before the blood draw is also advisable.
Liquidseq Actionable Gene Panel [23] Test: Booking, Price, and Results
